NSE · ASTRAZEN
Astrazeneca Pharma India Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,304 Cr with net profit ₹188 Cr — a 8.14% net margin, versus 6.59% the period before.
Shareholding
As of 2026-06-30
- Promoter75%
- Public16.24%
- FII2.68%
- DII6.08%
29,338 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.45× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd.(this company) | ₹17,151 Cr | 98.87 | 19.65 | 21.49% | 6.97% |
| Alivus Life Sciences Ltd. | ₹17,068 Cr | 27.45 | 5.12 | 16.94% | 23.28% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹11,799 Cr | 38.64 | 3.56 | 7.7% | 6.48% |
| Procter & Gamble Health Limited | ₹9,006 Cr | 27.03 | 17.17 | 62.32% | 24.91% |
| Gujarat Themis Biosyn Ltd. | ₹5,598 Cr | 119.81 | 7.39 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,537 Cr | 32.68 | 5.57 | 15.6% | 15.47% |
| Bajaj HealthCare Limited | ₹1,122 Cr | 19.93 | 2.11 | 8.81% | 2.81% |
| Anuh Pharma Limited | ₹914 Cr | 20.68 | 2.6 | 11.65% | 5.67% |
| Amanta Healthcare Limited | ₹784 Cr | 51.08 | 3.56 | 7.46% | 5.04% |
| Bafna Pharmaceuticals Ltd. | ₹728 Cr | 93.5 | 7.57 | 11.54% | 5.46% |
AI analysis
AI-generated · google/gemini-2.5-flashAstrazeneca Pharma India Ltd. has a market capitalization of Rs 20136 Cr. The company reported revenue of Rs 1756.92 Cr and a profit margin of 8.24%. Its earnings per share (EPS) are Rs 76.57.
Positives
- +The company has a low debt-to-equity ratio of 0.03.
- +Return on capital employed (ROCE) is 25.53%.
- +Return on equity (ROE) is 21.49%.
- +Promoter holding of 75% is high and stable.
- +No shares are pledged by the promoters.
Negatives
- −Revenue growth information is not available.
- −Profit margin is 8.24%, which may be considered moderate.
- −Earnings per share (EPS) decreased to Rs 46.3 in Mar 2025 from Rs 64.6 in Mar 2024.
- −Net profit decreased to Rs 115.74 Cr in Mar 2025 from Rs 161.51 Cr in Mar 2024.
- −Quarterly EPS figures are not available in the provided data.
Financial Performance
The company's revenue has shown growth over the past few years, reaching Rs 1756.92 Cr in Mar 2025 from Rs 826.4 Cr in Mar 2021. Net profit also increased from Rs 93.3 Cr in Mar 2021 to Rs 115.74 Cr in Mar 2025, though it saw a decline from Rs 161.51 Cr in Mar 2024. Earnings per share (EPS) were Rs 46.3 in Mar 2025, down from Rs 64.6 in Mar 2024.
Profitability & Returns
Astrazeneca Pharma India Ltd. achieved a return on equity (ROE) of 21.49% and a return on capital employed (ROCE) of 25.53%. The company's profit margin stood at 8.24%. Over the last five years, net profit has fluctuated, reaching a high of Rs 161.51 Cr in Mar 2024 before decreasing to Rs 115.74 Cr in Mar 2025.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.03, indicating a limited reliance on borrowed capital. For the latest available period, the book value per share is Rs 349.12. The company does not have any promoter share pledges.
Ownership & Pledges
There are no shares pledged by the promoters.
Data as of — price: 2026-09-10 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Astrazeneca Pharma India Ltd.share price & fundamentals